Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 open-label study of KRT-232 alone and with low-dose cytarabine or decitabine in acute myeloid leukemia
MOH_2020-12-06_009257Phase 2Not yet recruiting
- Sponsor
- Kartos Therapeutics
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of navtemadlin in acute myeloid leukemia (AML) (3 arms), sponsored by Kartos Therapeutics. Primary endpoints: Recommended phase 2 dose, Complete remission rate and 1 more. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
navtemadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2020-12-06_009257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-06_009257.